The Diagnostic Performance of 18F-PSMA-1007 PET/CT in Prostate Cancer Patients with Early Recurrence after Definitive Therapy with a PSA <10 ng/ml.

Aim: The prostate bed is one of the common sites of early recurrence of prostate cancer. The currently used PSMA ligands (Ga-PSMA-11 and Tc-PSMA) undergo early urinary clearance resulting in interfering physiological activity within and surrounding the prostate. This can result in sites of cancer recurrence being obscured.

A comparison of the diagnostic performance of F-PSMA-1007 and GA-PSMA-11 in the same patients presenting with early biochemical recurrence.

Objective: Accurate early assessment of biochemical recurrence is essential in determining the correct treatment plan for patients with prostate cancer. Gallium-68-prostate-specific membrane antigen-11 (Ga-PSMA-11) targeting PSMA has been at the forefront of imaging in biochemical recurrence however the emergence of fluorine-18 (F)-PSMA-1007 may prove to be advantageous over the Ga-PSMA-11 molecule due to its physical and physiologic al attributes. The aim of our study was to assess the diagnostic performance of F-PSMA-1007 as compared to that of Ga-PSMA-11 in the same patients who presented with biochemical recurrence.

Ga-PSMA PET/CT Replacing Bone Scan in the Initial Staging of Skeletal Metastasis in Prostate Cancer: A Fait Accompli?

Purpose: Ga ligands targeting prostate-specific membrane antigen (PSMA) are rapidly emerging as a significant step forward in the management of prostate cancer. PSMA is a type II transmembrane protein with high expression in prostate carcinoma cells. We prospectively evaluated the use of Ga-PSMA positron emission tomography/computed tomography (PET/CT) in patients with prostate cancer and compared the results to those for technetium-99m (Tc)-10-metacyloyloxydecyl dihydrogen phosphate (MDP) bone scintigraphy (BS).

Bladder hamartoma: a unique cause of urinary retention in a child with Goldenhar syndrome.

The bladder hamartoma is an extremely rare entity. We report on its presence in a 5-year-old boy with Goldenhar syndrome. Most probably, this is the first report of a bladder hamartoma presenting with obstruction of the bladder outlet resulting in urinary retention.

The role of the PCA3 assay in predicting prostate biopsy outcome in a South African setting.

Unlabelled: What's known on the subject? and What does the study add? The PCA3 assay has shown significant potential amongst the initial studies carried out in Western countries. This assay performed in line with previous studies. We have shown this marker to perform independent of prostatic volume and have identified potential indications for its use in our setting.